Do analysts prefer DCTH or INGN?

Delcath Systems currently has a consensus price target of $23.17, indicating a potential upside of 40.75%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Delcath Systems 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.86 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has better earnings & valuation, DCTH or INGN?

Delcath Systems has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Delcath Systems $85.23M 6.70 $2.70M $0.01 1,646.00 Inogen $348.67M 0.41 -$22.75M -$0.90 N/A

Is DCTH or INGN more profitable?

Delcath Systems has a net margin of 0.56% compared to Inogen's net margin of -6.94%. Delcath Systems' return on equity of 0.46% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Delcath Systems 0.56% 0.46% 0.42% Inogen -6.94% -13.17% -8.36%

Does the media prefer DCTH or INGN?

In the previous week, Delcath Systems and Delcath Systems both had 2 articles in the media. Inogen's average media sentiment score of 1.87 beat Delcath Systems' score of 0.98 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Delcath Systems 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer INGN or BWAY?

Brainsway has a consensus price target of $18.20, suggesting a potential upside of 25.34%. Given Brainsway's stronger consensus rating and higher probable upside, analysts clearly believe Brainsway is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Brainsway 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has better earnings & valuation, INGN or BWAY?

Brainsway has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inogen $348.67M 0.41 -$22.75M -$0.90 N/A Brainsway $52.22M 11.18 $7.57M $0.44 33.00

Is INGN or BWAY more profitable?

Brainsway has a net margin of 15.65% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.74% beat Inogen's return on equity. Company Net Margins Return on Equity Return on Assets Inogen -6.94% -13.17% -8.36% Brainsway 15.65% 12.74% 8.17%

Does the media refer more to INGN or BWAY?

In the previous week, Brainsway had 2 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Brainsway and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat Brainsway's score of 0.83 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Brainsway 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Do analysts prefer INGN or TCMD?

Tactile Systems Technology has a consensus target price of $38.40, indicating a potential upside of 67.10%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Tactile Systems Technology 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67

Does the media refer more to INGN or TCMD?

In the previous week, Tactile Systems Technology had 3 more articles in the media than Inogen. MarketBeat recorded 5 mentions for Tactile Systems Technology and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat Tactile Systems Technology's score of 1.70 indicating that Inogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Tactile Systems Technology 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts prefer NPCE or INGN?

NeuroPace currently has a consensus price target of $19.29, indicating a potential upside of 31.64%. Given NeuroPace's stronger consensus rating and higher possible upside, research analysts clearly believe NeuroPace is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NeuroPace 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has higher valuation & earnings, NPCE or INGN?

NeuroPace has higher earnings, but lower revenue than Inogen. NeuroPace is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NeuroPace $99.99M 5.03 -$21.47M -$0.57 N/A Inogen $348.67M 0.41 -$22.75M -$0.90 N/A

Is NPCE or INGN more profitable?

Inogen has a net margin of -6.94% compared to NeuroPace's net margin of -19.34%. Inogen's return on equity of -13.17% beat NeuroPace's return on equity. Company Net Margins Return on Equity Return on Assets NeuroPace -19.34% -105.64% -16.51% Inogen -6.94% -13.17% -8.36%

Does the media favor NPCE or INGN?

In the previous week, NeuroPace had 1 more articles in the media than Inogen. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat NeuroPace's score of 1.45 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroPace 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate CLPT or INGN?

ClearPoint Neuro presently has a consensus target price of $25.67, suggesting a potential upside of 69.53%. Given ClearPoint Neuro's higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Inogen. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ClearPoint Neuro 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Inogen 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Which has preferable valuation & earnings, CLPT or INGN?

Inogen has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ClearPoint Neuro $36.97M 12.49 -$25.54M -$1.18 N/A Inogen $348.67M 0.41 -$22.75M -$0.90 N/A

Is CLPT or INGN more profitable?

Inogen has a net margin of -6.94% compared to ClearPoint Neuro's net margin of -81.76%. Inogen's return on equity of -13.17% beat ClearPoint Neuro's return on equity. Company Net Margins Return on Equity Return on Assets ClearPoint Neuro -81.76% -188.09% -40.88% Inogen -6.94% -13.17% -8.36%

Does the media prefer CLPT or INGN?

In the previous week, ClearPoint Neuro had 2 more articles in the media than Inogen. MarketBeat recorded 4 mentions for ClearPoint Neuro and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat ClearPoint Neuro's score of 1.23 indicating that Inogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ClearPoint Neuro 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inogen 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Inogen (INGN) Competitors

$5.37 -0.13 (-2.36%)

Closing price 08/31/2026 04:00 PM Eastern

Extended Trading

$5.48 +0.11 (+2.07%)

As of 04:00 AM Eastern

Compare

INGN vs. DCTH, BWAY, TCMD, NPCE, and CLPT

Should you buy Inogen stock or one of its competitors? Inogen's main competitors and comparable companies include Delcath Systems (DCTH), Brainsway (BWAY), Tactile Systems Technology (TCMD), NeuroPace (NPCE), and ClearPoint Neuro (CLPT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Inogen compare to Delcath Systems?

Delcath Systems (NASDAQ:DCTH) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, dividends, valuation, profitability, earnings, institutional ownership and media sentiment.

Delcath Systems currently has a consensus price target of $23.17, indicating a potential upside of 40.75%. Given Delcath Systems' stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Delcath Systems	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

In the previous week, Delcath Systems and Delcath Systems both had 2 articles in the media. Inogen's average media sentiment score of 1.87 beat Delcath Systems' score of 0.98 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Delcath Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 19.4% of Delcath Systems shares are owned by insiders. Comparatively, 2.5% of Inogen shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Delcath Systems has higher earnings, but lower revenue than Inogen. Inogen is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Delcath Systems	$85.23M	6.70	$2.70M	$0.01	1,646.00
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A

Delcath Systems has a beta of 0.52, suggesting that its stock price is 48% less volatile than the broader market. Comparatively, Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Delcath Systems has a net margin of 0.56% compared to Inogen's net margin of -6.94%. Delcath Systems' return on equity of 0.46% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Delcath Systems	0.56%	0.46%	0.42%
Inogen	-6.94%	-13.17%	-8.36%

Summary

Delcath Systems beats Inogen on 11 of the 15 factors compared between the two stocks.

How does Inogen compare to Brainsway?

Inogen (NASDAQ:INGN) and Brainsway (NASDAQ:BWAY) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, valuation, risk, earnings, media sentiment, institutional ownership and dividends.

Brainsway has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Brainsway, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A
Brainsway	$52.22M	11.18	$7.57M	$0.44	33.00

Brainsway has a net margin of 15.65% compared to Inogen's net margin of -6.94%. Brainsway's return on equity of 12.74% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Brainsway	15.65%	12.74%	8.17%

Inogen has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Brainsway has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market.

Brainsway has a consensus price target of $18.20, suggesting a potential upside of 25.34%. Given Brainsway's stronger consensus rating and higher probable upside, analysts clearly believe Brainsway is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Brainsway	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Brainsway had 2 more articles in the media than Inogen. MarketBeat recorded 4 mentions for Brainsway and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat Brainsway's score of 0.83 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Brainsway	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

89.9% of Inogen shares are held by institutional investors. Comparatively, 30.1% of Brainsway shares are held by institutional investors. 2.5% of Inogen shares are held by company insiders. Comparatively, 19.0% of Brainsway shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Brainsway beats Inogen on 12 of the 17 factors compared between the two stocks.

How does Inogen compare to Tactile Systems Technology?

Inogen (NASDAQ:INGN) and Tactile Systems Technology (NASDAQ:TCMD) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, analyst recommendations, profitability, earnings, valuation and media sentiment.

In the previous week, Tactile Systems Technology had 3 more articles in the media than Inogen. MarketBeat recorded 5 mentions for Tactile Systems Technology and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat Tactile Systems Technology's score of 1.70 indicating that Inogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Tactile Systems Technology	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Inogen has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market. Comparatively, Tactile Systems Technology has a beta of 0.81, indicating that its stock price is 19% less volatile than the broader market.

Tactile Systems Technology has lower revenue, but higher earnings than Inogen. Inogen is trading at a lower price-to-earnings ratio than Tactile Systems Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A
Tactile Systems Technology	$329.52M	1.58	$19.09M	$1.08	21.28

89.9% of Inogen shares are owned by institutional investors. Comparatively, 83.4% of Tactile Systems Technology shares are owned by institutional investors. 2.5% of Inogen shares are owned by insiders. Comparatively, 2.1% of Tactile Systems Technology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Tactile Systems Technology has a consensus target price of $38.40, indicating a potential upside of 67.10%. Given Tactile Systems Technology's stronger consensus rating and higher probable upside, analysts clearly believe Tactile Systems Technology is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Tactile Systems Technology	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67

Tactile Systems Technology has a net margin of 7.10% compared to Inogen's net margin of -6.94%. Tactile Systems Technology's return on equity of 11.49% beat Inogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inogen	-6.94%	-13.17%	-8.36%
Tactile Systems Technology	7.10%	11.49%	9.17%

Summary

Tactile Systems Technology beats Inogen on 11 of the 17 factors compared between the two stocks.

How does Inogen compare to NeuroPace?

NeuroPace (NASDAQ:NPCE) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

NeuroPace has higher earnings, but lower revenue than Inogen. NeuroPace is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.03	-$21.47M	-$0.57	N/A
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A

78.8% of NeuroPace shares are held by institutional investors. Comparatively, 89.9% of Inogen shares are held by institutional investors. 19.2% of NeuroPace shares are held by company insiders. Comparatively, 2.5% of Inogen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Inogen has a net margin of -6.94% compared to NeuroPace's net margin of -19.34%. Inogen's return on equity of -13.17% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-19.34%	-105.64%	-16.51%
Inogen	-6.94%	-13.17%	-8.36%

In the previous week, NeuroPace had 1 more articles in the media than Inogen. MarketBeat recorded 3 mentions for NeuroPace and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat NeuroPace's score of 1.45 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

NeuroPace has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market. Comparatively, Inogen has a beta of 1.55, meaning that its stock price is 55% more volatile than the broader market.

NeuroPace currently has a consensus price target of $19.29, indicating a potential upside of 31.64%. Given NeuroPace's stronger consensus rating and higher possible upside, research analysts clearly believe NeuroPace is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

NeuroPace beats Inogen on 9 of the 16 factors compared between the two stocks.

How does Inogen compare to ClearPoint Neuro?

ClearPoint Neuro (NASDAQ:CLPT) and Inogen (NASDAQ:INGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings, media sentiment and risk.

ClearPoint Neuro presently has a consensus target price of $25.67, suggesting a potential upside of 69.53%. Given ClearPoint Neuro's higher possible upside, analysts plainly believe ClearPoint Neuro is more favorable than Inogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Inogen	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

ClearPoint Neuro has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Inogen has a beta of 1.55, suggesting that its stock price is 55% more volatile than the broader market.

Inogen has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Inogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$36.97M	12.49	-$25.54M	-$1.18	N/A
Inogen	$348.67M	0.41	-$22.75M	-$0.90	N/A

Inogen has a net margin of -6.94% compared to ClearPoint Neuro's net margin of -81.76%. Inogen's return on equity of -13.17% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-81.76%	-188.09%	-40.88%
Inogen	-6.94%	-13.17%	-8.36%

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 89.9% of Inogen shares are owned by institutional investors. 6.9% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 2.5% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, ClearPoint Neuro had 2 more articles in the media than Inogen. MarketBeat recorded 4 mentions for ClearPoint Neuro and 2 mentions for Inogen. Inogen's average media sentiment score of 1.87 beat ClearPoint Neuro's score of 1.23 indicating that Inogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inogen	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Inogen beats ClearPoint Neuro on 12 of the 17 factors compared between the two stocks.

Get Inogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding INGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

INGN vs. The Competition

Export

Metric	Inogen	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$145.96M	$5.83B	$7.20B	$12.89B
Dividend Yield	N/A	1.75%	2.54%	11.27%
P/E Ratio	-5.97	25.97	272.60	25.49
Price / Sales	0.41	71.49	627.57	97.10
Price / Cash	N/A	33.69	28.74	36.03
Price / Book	0.76	6.24	11.03	6.34
Net Income	-$22.75M	$149.14M	$3.47B	$349.45M
7 Day Performance	-3.07%	-0.90%	0.14%	-0.67%
1 Month Performance	-16.74%	6.16%	8.16%	4.48%
1 Year Performance	-32.79%	5.82%	24.14%	14.94%

Inogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
INGN Inogen	1.2069 of 5 stars	$5.37 -2.4%	N/A	-32.8%	$145.96M	$348.67M	N/A	1,030	Positive News
DCTH Delcath Systems	3.7602 of 5 stars	$16.75 -2.3%	$23.17 +38.3%	+49.4%	$594.74M	$85.23M	1,676.68	60
BWAY Brainsway	4.4289 of 5 stars	$14.19 -3.7%	$16.95 +19.5%	+86.6%	$591.53M	$52.22M	32.25	120	Analyst Forecast
TCMD Tactile Systems Technology	4.2716 of 5 stars	$23.36 -1.9%	$38.40 +64.4%	+72.7%	$539.58M	$329.52M	21.63	1,086	Positive News
NPCE NeuroPace	3.5335 of 5 stars	$13.99 -0.3%	$19.29 +37.9%	+60.1%	$481.57M	$99.99M	N/A	170

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:INGN) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Inogen (INGN) Competitors

INGN vs. DCTH, BWAY, TCMD, NPCE, and CLPT

How does Inogen compare to Delcath Systems?

Summary

How does Inogen compare to Brainsway?

Summary

How does Inogen compare to Tactile Systems Technology?

Summary

How does Inogen compare to NeuroPace?

Summary

How does Inogen compare to ClearPoint Neuro?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Inogen (INGN) Competitors

INGN vs. DCTH, BWAY, TCMD, NPCE, and CLPT

How does Inogen compare to Delcath Systems?

Do analysts prefer DCTH or INGN?

Does the media prefer DCTH or INGN?

Do institutionals and insiders believe in DCTH or INGN?

Which has better earnings & valuation, DCTH or INGN?

Which has more volatility and risk, DCTH or INGN?

Is DCTH or INGN more profitable?

Summary

How does Inogen compare to Brainsway?

Which has better earnings & valuation, INGN or BWAY?

Is INGN or BWAY more profitable?

Which has more volatility & risk, INGN or BWAY?

Do analysts prefer INGN or BWAY?

Does the media refer more to INGN or BWAY?

Do insiders and institutionals hold more shares of INGN or BWAY?

Summary

How does Inogen compare to Tactile Systems Technology?

Does the media refer more to INGN or TCMD?

Which has more volatility and risk, INGN or TCMD?

Which has preferable earnings & valuation, INGN or TCMD?

Do institutionals and insiders have more ownership in INGN or TCMD?

Do analysts prefer INGN or TCMD?

Is INGN or TCMD more profitable?

Summary

How does Inogen compare to NeuroPace?

Which has higher valuation & earnings, NPCE or INGN?

Do institutionals & insiders believe in NPCE or INGN?

Is NPCE or INGN more profitable?

Does the media favor NPCE or INGN?

Which has more risk & volatility, NPCE or INGN?

Do analysts prefer NPCE or INGN?

Summary

How does Inogen compare to ClearPoint Neuro?

Do analysts rate CLPT or INGN?

Which has more risk & volatility, CLPT or INGN?

Which has preferable valuation & earnings, CLPT or INGN?

Is CLPT or INGN more profitable?

Do institutionals & insiders have more ownership in CLPT or INGN?

Does the media prefer CLPT or INGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

INGN vs. The Competition

Inogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools